Related Experiment Video
Updated: May 15, 2025
Intranasal Administration of CNS Therapeutics to Awake Mice
Published on: April 8, 2013
Intranasal insulin enhances postoperative sleep quality and delirium in middle-aged cardiac surgery patients: A
Ming Yang1, Tong Lu1, Lei Cao1
1Department of Anesthesiology, Xinqiao Hospital of Chongqing, Second Affiliated Hospital of Army Medical University, PLA, Chongqing, China.
Background:
Postoperative delirium (POD) remains a significant complication following cardiopulmonary bypass (CPB) surgery, particularly in middle-aged patients who constitute the majority of this surgical population. While intranasal insulin (INI) has shown neuroprotective potential in aging cohorts, its efficacy in younger surgical patients and its underlying mechanisms remain under explored. This study investigates whether INI mitigates POD through sleep-wake cycle modulation.
Method:
It is a single-center prospective randomized, double-blinded controlled trial from March 4, 2024 to October 18, 2024. 76 middle-aged patients (45-65 years) undergoing elective CPB surgery were randomized to receive INI (20 IU) or placebo preoperatively and on postoperative days 1-2. The primary outcome was POD incidence (CAM-ICU criteria). Secondary outcomes included Mini-Mental State Examination (MMSE) scores, actigraphy-derived sleep metrics (sleep efficiency [SE], total sleep time [TST]). Analyses followed intention-to-treat principles.
Results:
INI significantly reduced POD incidence (17.1 % vs. 38.9 %, RR = 3.45, p = 0.037) and improved cognitive recovery, as evidenced by higher MMSE scores at postoperative day 5 with a difference of 1.71 (95 % CI, 0.19 to 3.23; p = 0.027). Sleep analysis revealed robust improvements in the INI group: SE increased by 21.3 % (78.2 ± 12.1 % vs. 64.5 ± 15.3 %, p = 0.031), and TST extended by 27.1 % (6.1 ± 1.2h vs. 4.8 ± 1.5h, p = 0.033) on postoperative day 1. No significant differences were observed in hospital length of stay (p = 0.893), highlighting the specificity of INI's sleep-mediated effects.
Conclusion:
This trial demonstrates that INI stabilizes postoperative sleep architecture, leading to reduced POD incidence and enhanced cognitive recovery in middle-aged CPB patients. These findings position INI as a targeted intervention for perioperative neurocognitive protection, particularly in populations vulnerable to circadian disruption.
Clinical Trial Registration:
ChiCTR 2400081444. Registered March 1, 2024, http://www.chictr.org.cn.
More Related Videos
07:54Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
05:44Novel Methods for Intranasal Administration Under Inhalation Anesthesia to Evaluate Nose-to-Brain Drug Delivery
Published on: November 14, 2018
Related Concept Videos
01:24General Anesthesia: Overview
General anesthesia induces unconsciousness in the whole body, while the others target specific areas or sensations. It is administered to minimize adverse effects, maintain...
01:22Stages of General Anesthesia
01:19Management of Insomnia
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:27Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
01:16Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...